1. Class action lawsuit filed against HIMS for securities fraud violations. 2. Allegations include false statements and deceptive marketing practices. 3. Investors from April to June 2025 eligible to join the lawsuit. 4. Risks of partnership termination with Novo Nordisk potentially impacting HIMS. 5. Investors encouraged to recover losses through participation in the class action.
The ongoing class action lawsuit raises significant legal risks, similar to past cases like Tesla's stock dip following legal issues stemming from misleading statements. Investors often react negatively, causing stock prices to drop.
The legal circumstances surrounding HIMS directly threaten its credibility and investor confidence, likely influencing future stock performance significantly.
The lawsuit's immediate implications may manifest quickly, leading to potential price drops as news spreads. Historical cases suggest stocks often react sharply to news of legal troubles.
LOS ANGELES, Aug. 18, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between April 29, 2025 and June 23, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before August 25, 2025.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Hims & Hers was engaged in marketing activities that Novo Nordisk would describe as "deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk." The Company was at risk of Novo Nordisk terminating their partnership. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Hims & Hers, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hims-investors-have-opportunity-to-lead-hims--hers-health-inc-securities-fraud-lawsuit-with-the-schall-law-firm-302531864.html
SOURCE The Schall Law Firm